
|Articles|June 21, 2004
Drug provides relief to those with overactive bladder
The FDA recently approved trospium (Sanctura, Indevus Pharmaceuticals/Odyssey Pharmaceuticals) for the treatment of OAB with symptoms of urge urinary incontinence, urgency, and urinary frequency. The product launch of trospium is expected to take place during the third quarter of 2004.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Q&A: TrumpRx Could Change the Way Pharmacies, PBMs Do Business
2
TrumpRx Promising Direct-to-Consumer Drugs for Discounted Prices
3
New Research Highlights Dietary Interventions to Potentially Manage Asthma
4
FDA Enforces Stricter Vaccine Development, Linking COVID Vaccine to Pediatric Deaths
5





































































































































